ProQR Therapeutics (NASDAQ:PRQR) Earns “Buy” Rating from HC Wainwright

ProQR Therapeutics (NASDAQ:PRQR)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $5.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 150.00% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Chardan Capital upped their target price on shares of ProQR Therapeutics from $2.00 to $2.50 and gave the company a “buy” rating in a research note on Thursday, March 14th. Citigroup lifted their price objective on shares of ProQR Therapeutics from $1.80 to $2.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Finally, StockNews.com cut shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $3.60.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $2.00 on Friday. ProQR Therapeutics has a 1-year low of $1.11 and a 1-year high of $3.29. The company has a market capitalization of $162.72 million, a PE ratio of -5.13 and a beta of 0.30. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.54 and a quick ratio of 3.54. The business has a 50-day moving average of $2.13 and a 200-day moving average of $1.94.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). The business had revenue of $3.54 million during the quarter, compared to the consensus estimate of $27.88 million. ProQR Therapeutics had a negative net margin of 431.65% and a negative return on equity of 56.71%. As a group, equities analysts forecast that ProQR Therapeutics will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Monaco Asset Management SAM boosted its holdings in shares of ProQR Therapeutics by 58.9% during the third quarter. Monaco Asset Management SAM now owns 377,517 shares of the biopharmaceutical company’s stock valued at $491,000 after acquiring an additional 140,000 shares during the period. BNP Paribas Financial Markets grew its position in ProQR Therapeutics by 120.1% in the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 19,100 shares during the last quarter. Finally, RFG Advisory LLC acquired a new stake in shares of ProQR Therapeutics in the first quarter valued at approximately $73,000. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).